Apixaban in Subjects With Peritoneal Dialysis

Inclusion Criteria: * Participant with 21\<BMI\<40 * French participant * Participant able to consent * Participant with social insurance * Participant on peritoneal dialysis for at least 3 months with end-stage renal disease treated Exclusion Criteria: * Participant with hypersensibility reactions to apixaban * Participant with a history of major bleeding * Participant already on anticoagulant * Participant on non-stearoid anti-inflammatory at anti-inflammatory dosage \> 300 mg * Participant on potent inhibitors of CYP 3A4 and P-gp * Participant on inducers of CYP3A4 and P-sp * Participant with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment * Participant receiving or having received antibiotic treatment within 14 days prior to study * Pregnant or lactating women * Participant with known hypersensitivity reactions to icodextrin * Participant not supporting an intraperitoneal volume of 2 liters (only participant with peritoneal dialysis) * Participant with "Normal renal function" with glomerular filtration rate \< 90 ml/min